Clinical Trial: Clomiphene in Males With Prolactinomas and Persistent Hypogonadism

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Recovery of Gonadal Function by Clomiphene in Males With Prolactinomas and Persistent Hypogonadism

Brief Summary: Prolactinomas are usually associated with hypogonadotropic hypogonadism in both sexes. Clomiphene citrate is a well known selective estrogen receptor modulator that increases gonadotropin secretion via hypothalamic-pituitary action. We conducted a prospective, open label clinical trial of CC to evaluate its effects in reverting persistent HH in male patients with prolactinomas under dopaminergic agonist treatment.

Detailed Summary:
Sponsor: Federal University of São Paulo

Current Primary Outcome: assess the effects of CC treatment on testosterone levels in male patients with prolactinomas and persistent HH on dopaminergic agonist therapy [ Time Frame: 10 days, 4, 8 and 12 weeks ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Assess the effects of CC on sexual function, fertility, body composition, lipid and glucose metabolism, and quality of life were also evaluated.

Original Secondary Outcome: Same as current

Information By: Federal University of São Paulo

Dates:
Date Received: June 12, 2008
Date Started: June 2004
Date Completion:
Last Updated: June 13, 2008
Last Verified: June 2008